Please amend the above-identified application as follows:

IN THE CLAIMS

Please add claims 47 to 54:

47. A method of treating a patient having chronic HCV infection which comprises administering to said patient a therapeutically effective amount of a combination therapy of pegylated interferon-alfa and ribavirin for a time sufficient to substantially lower HCV-RNA in association with a therapeutically effective amount of Vitamin E and Vitamin C for a time sufficient to ameliorate ribavirin-related hemolysis.
48. The method of claim 47 wherein the pegylated interferon alfa is pegylated interferon alfa-2a.
49. The method of claim 47 wherein the pegylated interferon alfa is pegylated interferon alfa-2b.
50. The method of claim 47 wherein the time for administering the combination therapy in association with the therapeutically effective amount of Vitamin E and Vitamin C and is a period of at least about 24 weeks.
51. The method of claim 47 wherein the time for administering the combination therapy in association with the therapeutically effective amount of Vitamin E and Vitamin C and is a period of at least about 48 weeks.
52. A method of treating a patient having a chronic HCV infection which comprises administering to said patient for a time period of at least about 24 weeks a therapeutically effective amount of a combination therapy of pegylated interferon alfa and ribavirin sufficient to lower detectable HCV-RNA in association with a therapeutically effective amount of Vitamin E and Vitamin C sufficient to ameliorate ribavirin-related hemolysis.
53. The method of claim 52 wherein the patient has a HCV genotype 2 or 3 infection.
54. The method of claim 52 wherein the patient has a HCV genotype 1 infection, and the time period is about 48 weeks.